BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?

Company Will Earn Nearly $20bn In 2021

 
• By Andrew McConaghie

Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
Pfizer and BioNTech now expect to deliver 2.5 billion doses of Comirnaty this year, putting them far ahead of mRNA vaccine rivals Moderna. • Source: Alamy

More from Business

More from Scrip